Media Room

H1 Revenues of $7.6 million and Controlled Net Loss   MISSISSAUGA, CANADA, May 14, 2026 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its second quarter and first half of fiscal 2026 ended March 31, 2026 (“Q2” and “H1”).   Results for Q2 and H1 […]

Microbix announces announces it will be attending and presenting at the 2026 Bloom Burton & Co. Healthcare Investor Conference (the “Conference”) taking place at the Metro Toronto Convention Centre, North Building, on April 21 and 22, 2026.

Microbix announces announces it will be attending and presenting at the 2026 Bloom Burton & Co. Healthcare Investor Conference (the “Conference”) taking place at the Metro Toronto Convention Centre, North Building, on April 21 and 22, 2026.

Microbix announces announces it will be attending and presenting at the 2026 Bloom Burton & Co. Healthcare Investor Conference (the “Conference”) taking place at the Metro Toronto Convention Centre, North Building, on April 21 and 22, 2026.

Microbix announces announces it will be attending and presenting at the 2026 Bloom Burton & Co. Healthcare Investor Conference (the “Conference”) taking place at the Metro Toronto Convention Centre, North Building, on April 21 and 22, 2026.

Microbix announces that it will be exhibiting at ESCMID Global 2026 and presenting results of a novel quality assessment product (“QAP™”) to enable full-process quality management of molecular assays to detect an RNA-based virus (e.g., “RT-PCR” tests).

Microbix announces the voting results from the Annual Meeting of Shareholders of the Company (the “Meeting”) which was held on March 25, 2026.

Microbix announces that it is presenting results of novel QUANTDx™ reference materials designed to emulate real-life human papillomavirus (“HPV”) patient-samples and thereby better support the validation of molecular (e.g., “PCR”) tests for infection. Microbix is presenting at EUROGIN, an international conference and exhibition focused upon innovations in HPV research and global cancer solutions taking place in Vienna, Austria from March 18 to 21, 2026.

Microbix announces that the contract development and manufacturing organization (“CDMO”) engaged by its funding and commercialization partner, Sequel Pharma, LLC (“Sequel”), has modernized production methods for the active ingredient (i.e., “Drug Substance”) of Kinlytic® urokinase (“Kinlytic”), a biologic for dissolving blood clots.